The ICMR and Panacea Biotec have initiated the first-ever phase three clinical trial for developing a dengue vaccine in India, the Union Health Ministry said on Wednesday. India's indigenous tetravalent dengue vaccine, DengiAll, has been developed by Panacea Biotec and the first participant in this trial was vaccinated on Wednesday at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak.

联合卫生部周三表示，ICMR和Panacea Biotec已经启动了有史以来第一个在印度开发登革热疫苗的三期临床试验。印度本土四价登革热疫苗登革热（DengiAll）由Panacea Biotec开发，该试验的第一名参与者于周三在罗塔克Pandit Bhagwat Dayal Sharma医学研究生院接种。

The phase three clinical trial will be conducted across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants. 'The initiation of this phase three clinical trial for India's first indigenous dengue vaccine marks a critical advancement in our fight against dengue.

第三阶段临床试验将在18个州和联邦地区的19个地点进行，涉及10335多名健康成人参与者。”印度第一个本土登革热疫苗的第三阶段临床试验的启动标志着我们抗击登革热的关键进展。

It reflects our commitment to protecting our citizens from this pervasive disease and underscores India's capabilities in vaccine research and development,' Union Health Minister J P Nadda said. 'Through this collaboration between ICMR and Panacea Biotec, we are not only taking a step towards ensuring the health and well-being of our people but also reinforcing our vision of Atmanirbhar Bharat in the healthcare sector,' he said.

欧盟卫生部长纳达（J P Nadda）说，这反映了我们保护公民免受这种普遍疾病侵害的承诺，并突显了印度在疫苗研发方面的能力他说，通过ICMR和Panacea Biotec的合作，我们不仅朝着确保人民的健康和福祉迈出了一步，而且加强了我们在医疗保健领域对Atmanirbhara Bharat的愿景。

Currently, there is no antiviral treatment or licensed vaccine against dengue in India. The development of an effective vaccine is complex due to the need to achieve good efficacy for all four serotypes. In India, all four serotypes of dengue virus are known to circulate or co-circulate in many regions, the ministry statement said.

目前，印度没有针对登革热的抗病毒治疗或许可疫苗。由于需要对所有四种血清型取得良好的疗效，因此有效疫苗的开发是复杂的。该部声明称，在印度，已知所有四种登革热病毒血清型在许多地区传播或共同传播。

The tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH), USA, has shown promising results in preclinical and clinical trials worldwide. Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of d.

最初由美国国立卫生研究院（NIH）开发的四价登革热疫苗株（TV003/TV005）在全球临床前和临床试验中显示出有希望的结果。Panacea Biotec是接受该菌株的三家印度公司之一，目前处于d的最晚期。